RESULTS OF INDUCTION AND CONSOLIDATION TREATMENT WITH INTERMEDIATE AND HIGH‐DOSE ARA‐C AND m‐AMSA CONTAINING REGIMENS IN PATIENTS WITH PRIMARILY FAILED OR RELAPSED ACUTE LEUKEMIA AND NON‐HODGKIN'S LYMPHOMA

This publication has 12 references indexed in Scilit:

• Intermediate and high-dose ARA-C and m-AMSA (or daunorubicin) as remission and consolidation treatment for patients with relapsed acute leukaemia and lymphoblastic non-Hodgkin lymphoma
  Scandinavian Journal of Haematology, 2009
• High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia.
  Journal of Clinical Oncology, 1984
• The use of intermediate dose cytosine arabinoside (ID Ara‐C) in the treatment of acute non‐lymphocytic leukaemia in relapse
  British Journal of Haematology, 1984
• High-dose cytosine arabinoside: response to therapy in acute leukaemia and non-Hodgkin's lymphoma
  Cancer Chemotherapy and Pharmacology, 1984
• Therapy of Secondary Acute Nonlymphocytic Leukemia with Cytarabine
  New England Journal of Medicine, 1983
• Selective Antimicrobial Modulation of Human Microbial Flora: Infection Prevention in Patients with Decreased Host Defense Mechanisms by Selective Elimination of Potentially Pathogenic Bacteria
  The Journal of Infectious Diseases, 1981
• Ara-C lung: Noncardiogenic pulmonary edema complicating cytosine arabinoside therapy of leukemia
  The American Journal of Medicine, 1981
• Acute Leukemia: Biology and Treatment
  Annals of Internal Medicine, 1979
• Advances in the Treatment of Acute Myelogenous Leukemia
  New England Journal of Medicine, 1979
• Progress in the treatment of adults with acute leukemia: review of regimens containing cytarabine studied by the Southwest Oncology Group
  Archives of internal medicine (1960), 1976